Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Crisis

Friday, March 27, 2015

On March 26, Moscow hosted a Russian Association of Pharmaceutical Marketing (RAPM) conference, “New Threats and Opportunities of Russian Pharmaceutical Market in 2015”. Within the agenda of the conference, RNC Pharma published a forecast of the Russian pharmaceutical market after the monetary crisis of 2014-2015.

Any crisis is accompanied by a surge of the regulatory activity of the state, with the consequences for the future development of the market being often as serious as those of the crisis. That was the case in 2009-2010, when the market was getting used to functioning under the current price regulation, and that will be the case in 2015-2016, but there are many more regulation initiatives now.

Apparently, the most crucial for the market will be the change of the process of state import of pharmaceutical drugs, in particular the limitation of the access to bids for those foreign pharmaceutical drugs that have 2 or more alternatives of Russian, Belorussian or Kazakhstan origin.

The legalization of parallel import of pharmaceutical drugs to Russia, long-term contracts with suppliers, the development of public pharmacies as well as a possibility of compulsory licensing of pharmaceutical drugs may also have serious consequences for the market.

Please download the Powerpoint presentation here.